Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy.
Jessa E MillerJennifer L Taylor-CousarJonathan B OverdevestAastha KhatiwadaJess C MaceJeremiah A AltTodd E BodnerNaweed I ChowdhuryEmily A DiMangoPatricia H EshaghianAnne E GetzDavid A GudisEthan J HanPeter H HwangClaire L KeatingAshoke R KhanwalkarAdam J KimpleJivianne T LeeDouglas LiKarolin MarkarianMeghan NorrisJayakar V NayakCameran OwensZara M PatelKatie PochRodney J SchlosserKristine A SmithTimothy L SmithZachary M SolerJeffrey D SuhJeremy P TervoGrant A TurnerMarilene B WangMilene T SaavedraDaniel M BeswickPublished in: International forum of allergy & rhinology (2023)
The QOD MCID in PwCF was estimated to be 3.7. Elexacaftor/tezacaftor/ivacaftor led to qualitative but not clinically meaningful improvements in QOD score for most PwCF; PwCF with worse baseline QOD scores and nasal polyps improved in a clinically significant manner.